Effects of cancer disease on the metabolism of anticancer agents

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

ESMO open·2026

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.

ESMO open·2025

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

British journal of cancer·2023

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.

ESMO open·2022

COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC).

ESMO open·2021

Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.

Biochemical pharmacology·2017

Nucleic acid therapeutics for reinvigorating p53 function in glioblastoma: concepts, limitations and recent advances.

Pharmacology & therapeutics·2026

Navigating the landscape of stem cell therapeutics: Overcoming translational hurdles via emerging technologies and regulatory frontiers.

Pharmacology & therapeutics·2026

Prospects for adiponectin-based therapeutics in myocardial ischemia reperfusion injury.

Pharmacology & therapeutics·2026

Mitochondrial dysfunction in Alzheimer's disease: mechanisms, pathogenic interplay, and therapeutic opportunities.

Pharmacology & therapeutics·2026

Sinoatrial node dysfunction: molecular mechanisms, arrhythmogenesis, and translational pathways toward precision therapy.

Pharmacology & therapeutics·2026

Targeting KCC2 and NKCC1 for spinal motor dysfunction: pharmacology, therapeutic opportunities, and translational roadmap.

Pharmacology & therapeutics·2026

Calcineurin-mediated regulation of macrophage plasticity drives anti-tumor activity.

Molecular therapy. Advances·2026

EXO1 inhibition selectively kills replication repair-deficient cancer cells.

NAR cancer·2026

Biotics-based modulation of gastric precancerous states: microbial, metabolic, and epithelial mechanisms.

Frontiers in immunology·2026

Pan-cancer biomarkers of immune therapy resistance: mechanisms and clinical translation.

Frontiers in cell and developmental biology·2026

DYRK1A - a gene dose paradox.

Frontiers in cell and developmental biology·2026

Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer.

Theranostics·2026

Related Experiment Videos

Effects of cancer disease on the metabolism of anticancer agents

Related Concept Videos

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.

COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC).

Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.

Nucleic acid therapeutics for reinvigorating p53 function in glioblastoma: concepts, limitations and recent advances.

Navigating the landscape of stem cell therapeutics: Overcoming translational hurdles via emerging technologies and regulatory frontiers.

Prospects for adiponectin-based therapeutics in myocardial ischemia reperfusion injury.

Mitochondrial dysfunction in Alzheimer's disease: mechanisms, pathogenic interplay, and therapeutic opportunities.

Sinoatrial node dysfunction: molecular mechanisms, arrhythmogenesis, and translational pathways toward precision therapy.

Targeting KCC2 and NKCC1 for spinal motor dysfunction: pharmacology, therapeutic opportunities, and translational roadmap.

Calcineurin-mediated regulation of macrophage plasticity drives anti-tumor activity.

EXO1 inhibition selectively kills replication repair-deficient cancer cells.

Biotics-based modulation of gastric precancerous states: microbial, metabolic, and epithelial mechanisms.

Pan-cancer biomarkers of immune therapy resistance: mechanisms and clinical translation.

DYRK1A - a gene dose paradox.

Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer.

Related Experiment Videos

Effects of cancer disease on the metabolism of anticancer agents

Related Concept Videos

Related Articles